Page 5,868«..1020..5,8675,8685,8695,870..5,8805,890..»

Lovejoy Hospice – Video

Posted: Published on January 13th, 2013

Lovejoy Hospice Thank you to the following sponsors for helping with the production of our video: - Home Health Medical Express - Hull Hull Funeral Directors - Grants Pass Pharmacy - Southern Oregon Medical Equipment By: Lovejoy Hospice … Continue reading

Posted in Pharmacy | Comments Off on Lovejoy Hospice – Video

Pharmacy Owner Shoots And Kills Armed Assailant – UPDATED

Posted: Published on January 13th, 2013

MADERA, Calif. (KMPH) - UPDATE: KMPH had a chance to talk with the pharmacy owner as he describes the events. Take a look at the video above. Pharmacy owner is forced to shoot in defense as armed assailants attack. Investigators say 31-year-old Aquilla Bailey was one of two men who walked into a pharmacy near Almond avenue and Highway 99 in Madera, and started shooting. A pharmacy worker was hit in the leg. The pharmacy owner, Bryan Lee, heard shots and used his handgun to fire back, hitting Aquilla at least three times. The two men then ran out of the pharmacy, Aquilla collapsed and died. The man that got away was later discovered to be Jonte Harris, who has since been arrested. The worker shot at the pharmacy is expected to be okay. At this point, detectives don't know if the men were at the pharmacy to rob it, or if they were planning to kill the two people inside. Read the rest here: Pharmacy Owner Shoots And Kills Armed Assailant - UPDATED … Continue reading

Posted in Pharmacy | Comments Off on Pharmacy Owner Shoots And Kills Armed Assailant – UPDATED

BioTime Files Protocol To Start Human Clinical Trials Of Renevia In Europe

Posted: Published on January 12th, 2013

By RTT News, January 10, 2013, 09:17:00 AM EDT (RTTNews.com) - BioTime Inc. ( BTX ) announced it has submitted a Clinical Investigation Protocol to European regulatory authorities for approval to initiate studies for Renevia stem cell delivery platform. BioTime is currently completing the production of clinical materials according to current Good Manufacturing Practice regulations. The initiation of human clinical studies is expected in the second quarter of current year upon approval of the Clinical Investigation Protocol. Renevia, a member of the company's HyStem family of hydrogels, is a proprietary formulation that mimics the human extracellular matrix, a web of molecules surrounding cells that is essential to cellular function. Renevia is designed to be a liquid injectable matrix capable of safely polymerizing in the body into a three-dimensional tissue-like scaffold in combination with transplanted cells. For comments and feedback: contact editorial@rttnews.com http://www.rttnews.com Read the original post: BioTime Files Protocol To Start Human Clinical Trials Of Renevia In Europe … Continue reading

Posted in Stem Cell Human Trials | Comments Off on BioTime Files Protocol To Start Human Clinical Trials Of Renevia In Europe

Stem Cell Research Wins A Final Legal Battle

Posted: Published on January 12th, 2013

(Credit: ANNE-CHRISTINE POUJOULAT/AFP/Getty Images) By Pat Loeb PHILADELPHIA (CBS) Local researchers are hailing the announcement that the Supreme Court will not take up the issue of embryonic stem cell research. The court refused to review the dismissal of a lawsuit challenging funding for the research. The decision is good news for researchers at Penn and the Stem Cell Institute of New Jersey, who use stem cells to explore treatment for a wide variety of diseases. But, ultimately, says Jonathan Moreno of Penns bioethics center, its patients who benefit. People who have diseases that, if not directly treated, will be much better understood because of access to human embryonic stem cells, says Moreno. He hopes the decision will remove the stigma that plagued the research as opponents argued the morality of using cells from embryos left over from in vitro fertilization. (Father Tad Pacholczyk Credit: Pat Loeb) This raises very significant moral concerns and thats why this has been so much in the eye of the public, he explains. Read more: Stem Cell Research Wins A Final Legal Battle … Continue reading

Comments Off on Stem Cell Research Wins A Final Legal Battle

End to stem cell research challenge doesn't calm funding fears for scientists

Posted: Published on January 12th, 2013

Even as they celebrate clearing a legal hurdle, worries of stem cell research grant money evaporating constantly weigh on scientists like Dr. Ted Dawson, whose projects at Johns Hopkins Hospital have helped inform treatment of neurological diseases like Parkinson's and Alzheimer's. A three-year court battle by two researchers to stop stem cell research using human embryos ended Monday when the Supreme Court declined to review the case. Scientists like Dawson say that frees up grant opportunities and are relieved for now. "It takes some of the uncertainty out," Dawson said. "It takes us back to a situation where we're hopefully only limited by our creativity, our talent in doing the science and the resources available." The problem is that more limitations appear likely. Research advocates fear a handful of threats to funding for all types of stem cell research and scientific study in general: the so-called "fiscal cliff," more legal challenges, an eventual new administration in Washington and the possibility of a more competitive peer review process. Altogether, the hazards have tempered researchers' enthusiasm over the high court's non-decision. "It's good for research in general," said Dan Gincel, director of the Maryland Stem Cell Research Fund. "It doesn't stop any … Continue reading

Comments Off on End to stem cell research challenge doesn't calm funding fears for scientists

The Most Interesting Thing at JPMorgan's Health Care Conference

Posted: Published on January 12th, 2013

By Brian Orelli | More Articles January 11, 2013 | JPMorgan's health care conference is a treasure-trove of information about health care companies. From basic information to fourth quarter sales, even a few deals are signed, sealed, and announced at JPMorgan. But the most interesting -- both entertaining and educational -- part of the meeting happened virtually when attendees and remote observers of the conference piled onto a Twitter hashtag, #jpmpickuplines, scientifically mocking what an attendee might say to pick up someone at the hotel bar. "Best set of data points I've seen all year," tweeted San Francisco Business Times reporter Ron Leuty who started the meme. The top one -- as measured by retweets -- came from Roche's official Genentech Twitter account that tweeted, "Nice antibody. Wanna conjugate?" Educational? The meme is clearly entertaining -- well at least most of them, some got a little raunchy -- and it highlights that investors and companies can have a little fun. Investing may be serious, but it doesn't have to be stuffy. But the list of pickup lines also serves as a nice glossary of terms that every biotech investor should know. Genentech's tweet, for example, refers to the process of … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on The Most Interesting Thing at JPMorgan's Health Care Conference

Sarepta May Seek Partnership Advice for Experimental Drug

Posted: Published on January 12th, 2013

Sarepta Therapeutics Inc. (SRPT), a developer of an experimental drug for Duchenne muscular dystrophy, may seek advisers to find an overseas partner for the therapy, Chief Executive Officer Christopher Garabedian said. The biotechnology company is talking with more than a dozen drugmakers about a partnership for international sales of eteplirsen, Sareptas medicine for the rare muscle-wasting disease, Garabedian said in an interview at the JPMorgan Chase & Co. health-care conference in San Francisco. Cambridge, Massachusetts-based Sarepta is considering hiring an advisory firm, such as Centerview Partners LLC or JSP Partners, to help with the talks. The company isnt for sale, he said. While successful testing of eteplirsen may make Sarepta, a 32-year-old company with no marketed products, an acquisition target, Garabedian said he wants it to become a rival to large biotechnology companies such as Gilead Sciences Inc. (GILD), the worlds biggest maker of AIDS medicines and Celgene Corp. (CELG), the maker of the $3 billion cancer drug, Revlimid. Im building a team that knows how to create a successful global biopharmaceutical company, Garabedian said. Im hiring people from Genzyme, Gilead, Celgene, Shire, and Vertex. Those people like myself want to work on the next break-out biotech. Duchenne muscular dystrophy … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta May Seek Partnership Advice for Experimental Drug

Awesome Autism T-Shirts with a Mission – Video

Posted: Published on January 12th, 2013

Awesome Autism T-Shirts with a Mission Like Autism Live on Facebook at facebook.com Robert Thornton shares the Paper Cloud Apparel mission to help individuals with special needs by featuring their art work on T-shirts. Paper Clouds Apparel partners with organizations to help them raise funds and also hires individuals with special needs to work within their organization. Currently Paper Clouds Apparel is featuring art work by two children with Autism. The sale of these shirts will benefit the Center for Autism and Related Disorders, the world?s largest provider of a treatment to individuals with Autism Spectrum Disorders. Check out this amazing site http://www.papercloudsapparel.com for more information on these amazing shirts and special kids who designed them. The boy shirt was actually designed by Shannon Penrod?s son. There is a special incentive for the first 20 customers who buy shirts and mention Autism Live! Autism Live is a production of the Center for Autism and Related Disorders (CARD), headquartered in Tarzana, California, and with offices throughout the United States and around the globe. For more information on therapy for autism and other related disorders, visit the CARD website at centerforautism.com By: AutismLive … Continue reading

Comments Off on Awesome Autism T-Shirts with a Mission – Video

Miller, Beall to tackle issues

Posted: Published on January 12th, 2013

Another effort to provide insurance coverage for autism treatment and a proposal to bring agricultural education to more Iowa students are among the things a pair of Fort Dodge lawmakers will work on this year. State Sen. Daryl Beall and state Rep. Helen Miller, who are both Democrats, are preparing several bills for consideration during the legislative session that will start Monday. They are also getting ready to work on the state budget, which is expected to feature a surplus of up to $1 billion. Beall and Miller said they don't want the state to go on a spending spree. ''I definitely want us to be cautious and not rush out and start a bunch of programs,'' Miller said. Beall said he doesn't want to see legislators ''splashing money all around the place.'' The senator said he will resume his efforts to provide insurance coverage for an autism treatment called applied behavioral analysis. Inspired by a grandson who has autism, Beall introduced and passed legislation in 2010 that secured such insurance coverage for children of state employees. Last year, he introduced a bill that would mandate such insurance coverage for all Iowa children. The bill passed the Senate 43-7, but … Continue reading

Comments Off on Miller, Beall to tackle issues

Parents Fight To Get New Autism Treatment Covered

Posted: Published on January 12th, 2013

Health | Oregon OPB | Jan. 11, 2013 midnight | Updated: Jan. 11, 2013 7:05 a.m. | Portland, Oregon Portland mom Anastasia Puha has her hands full. Not only does she have four little girls, but Mili, her four-year-old, is autistic. "(Her) speech didn't develop," she says. "Really sensitive to noise and light and texture and just pretty cranky, pretty cranky child." Kristian Foden-Vencil / OPB Anastasia Puha with four-year-old Mili Puha says Mili has tantrums where she'll hit her head, scratch herself and bite.To reduce those tantrums, Mili has the relatively new treatment 'Applied Behavior Analysis' or ABA therapy. "One of the biggest things that I think she learned from ABA is, we can go to the store," she said. "Or we can walk into therapy together, before she would run away or throw herself down and you couldn't really pick her back up. And so she'll walk with me and that's just amazing. Ha ha ha." Applied Behavior Analysis is expensive - because it involves one-on-one attention. A 20-hour-a-week regimen can cost $50,000 a year. Jennifer Kessel is Mili's ABA therapist. She's has a BA in psychology and is employed by 'Building Bridges' -- a Portland company that … Continue reading

Comments Off on Parents Fight To Get New Autism Treatment Covered

Page 5,868«..1020..5,8675,8685,8695,870..5,8805,890..»